Palisade Bio, Inc. (PALI)Healthcare | Biotechnology | Denver, United States | NasdaqCM
2.00 USD
-0.11
(-5.213%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 2.00 +0.00 (0.030%) ⇧ (Aug. 28, 2026, 7:30 p.m. EDT) |
Hot Take ↕ | Aug. 22, 2026, 2:37 a.m. EDT
The immediate outlook is neutral-to-slightly-bearish due to heavy short interest and a lack of clear catalysts, despite the stock trading near its 52-week highs relative to its depressed lows. However, the long-term investment case is severely compromised by a catastrophic multi-year decline; the asset has lost virtually all its value over the last nine years, with seven consecutive years of negative returns ending in another sharp drop. This persistent structural deterioration suggests the market has permanently reassessed the business quality downward, rendering any current valuation metrics meaningless. Furthermore, there is no income component to offset the capital loss, as the company has not paid a dividend in five years. While analysts project significant upside based on potential clinical milestones, the historical price trajectory indicates these expectations have been repeatedly failed or priced in at a discount that offers no margin of safety. |
| Model | MAE |
|---|---|
| AutoETS ✓ | 0.038709 |
| MSTL | 0.053531 |
| AutoARIMA | 0.058130 |
| AutoTheta | 0.070765 |
Forecast horizon: 45 days | Selected: AutoETS
| Forecast Reliability | |
|---|---|
| Score | 44% |
| H-stat | 0.52 |
| Ljung-Box p | 0.002 |
| Jarque-Bera p | 0.675 |
| Excess Kurtosis | -0.56 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Revenue per Share | 0.003 |
| Market Cap | 348,541,120 |
| Trailing P/E | 3.08 |
| Forward P/E | -7.14 |
| Beta | 1.54 |
| Previous Name | Seneca Biopharma, Inc. |
| Website | https://www.palisadebio.com |
| Attribute | Value |
|---|---|
| 52 Week Change | 2.1969697 |
| Address1 | 4,600 South Syracuse Street |
| Address2 | Suite 900 |
| All Time High | 5,627,700.0 |
| All Time Low | 0.53 |
| Ask | 2.63 |
| Ask Size | 2 |
| Average Analyst Rating | 1.1 - Strong Buy |
| Average Daily Volume10 Day | 1,575,490 |
| Average Daily Volume3 Month | 2,949,631 |
| Average Volume | 2,985,079 |
| Average Volume10Days | 1,575,490 |
| Beta | 1.538 |
| Bid | 2.05 |
| Bid Size | 3 |
| Book Value | 0.701 |
| City | Denver |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 2.0 |
| Current Ratio | 24.258 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 2.1116 |
| Day Low | 1.99 |
| Display Name | Palisade Bio |
| Dividend Date | 1,563,408,000 |
| Earnings Timestamp End | 1,755,288,000 |
| Earnings Timestamp Start | 1,754,942,400 |
| Ebitda | -35,346,500 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -6.862 |
| Enterprise To Revenue | 485.082 |
| Enterprise Value | 242,540,880 |
| Eps Current Year | -0.22571 |
| Eps Forward | -0.28 |
| Eps Trailing Twelve Months | 0.65 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 2.0088 |
| Fifty Day Average Change | -0.00880003 |
| Fifty Day Average Change Percent | -0.0043807398 |
| Fifty Two Week Change Percent | 210.29413 |
| Fifty Two Week High | 2.86 |
| Fifty Two Week High Change | -0.8599999 |
| Fifty Two Week High Change Percent | -0.30069926 |
| Fifty Two Week Low | 0.53 |
| Fifty Two Week Low Change | 1.47 |
| Fifty Two Week Low Change Percent | 2.773585 |
| Fifty Two Week Range | 0.53 - 2.86 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,175,261,400,000 |
| Float Shares | 138,851,810 |
| Forward Eps | -0.28 |
| Forward P E | -7.142857 |
| Free Cashflow | -8,654,125 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 14 |
| Fullday Change | -0.11 |
| Fullday Change Percent | -5.21327 |
| Fullday Price | 2.0006 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 1.0 |
| Gross Profits | 500,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.01687 |
| Held Percent Institutions | 1.0149701 |
| Implied Shares Outstanding | 174,270,558 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,712,534,400 |
| Last Split Factor | 1:15 |
| Long Business Summary | Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibrostenotic Crohn's disease. The company has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; license agreement with the Regents of the University of California for sole purpose of maintaining the Newsoara Co-Development; and a co-development and distribution agreement with Newsoara Biopharma Co., Ltd. The company was founded in 2001 and is headquartered in Denver, Colorado. |
| Long Name | Palisade Bio, Inc. |
| Market | us_market |
| Market Cap | 348,541,120 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_244367385 |
| Most Recent Quarter | 1,782,777,600 |
| Name Change Date | 2,026-08-28 |
| Net Income To Common | -31,941,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 367,260,524 |
| Number Of Analyst Opinions | 9 |
| Open | 2.1 |
| Operating Cashflow | -18,190,000 |
| Operating Margins | -23.396002 |
| Payout Ratio | 0.0 |
| Phone | 858 704 4900 |
| Post Market Change | 0.00060009956 |
| Post Market Change Percent | 0.030004978 |
| Post Market Price | 2.0006 |
| Post Market Time | 1,787,959,805 |
| Prev Name | Seneca Biopharma, Inc. |
| Previous Close | 2.11 |
| Price Eps Current Year | -8.860928 |
| Price Hint | 4 |
| Price To Book | 2.8530672 |
| Price To Sales Trailing12 Months | 697.0822 |
| Profit Margins | 0.0 |
| Quick Ratio | 23.956 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.125 |
| Region | US |
| Regular Market Change | -0.11 |
| Regular Market Change Percent | -5.21327 |
| Regular Market Day High | 2.1116 |
| Regular Market Day Low | 1.99 |
| Regular Market Day Range | 1.99 - 2.1116 |
| Regular Market Open | 2.1 |
| Regular Market Previous Close | 2.11 |
| Regular Market Price | 2.0 |
| Regular Market Time | 1,787,947,200 |
| Regular Market Volume | 2,127,082 |
| Return On Assets | -0.32979 |
| Return On Equity | -0.51365 |
| Revenue Per Share | 0.003 |
| Sand P52 Week Change | 0.1966995 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 174,270,558 |
| Shares Percent Shares Out | 0.1916 |
| Shares Short | 33,391,318 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 37,022,896 |
| Short Name | Palisade Bio, Inc. |
| Short Percent Of Float | 0.1917 |
| Short Ratio | 16.29 |
| Source Interval | 15 |
| State | CO |
| Symbol | PALI |
| Target High Price | 25.0 |
| Target Low Price | 5.0 |
| Target Mean Price | 10.22222 |
| Target Median Price | 8.0 |
| Total Cash | 125,172,000 |
| Total Cash Per Share | 0.718 |
| Total Debt | 0 |
| Total Revenue | 500,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | 0.65 |
| Trailing P E | 3.0769231 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 1.94305 |
| Two Hundred Day Average Change | 0.056949973 |
| Two Hundred Day Average Change Percent | 0.029309576 |
| Type Disp | Equity |
| Volume | 2,127,082 |
| Website | https://www.palisadebio.com |
| Zip | 80,237 |